{"doi":"10.1101/2022.07.21.501010","title":"Durability of the Neutralizing Antibody Response to mRNA Booster Vaccination Against SARS-CoV-2 BA.2.12.1 and BA.4/5 Variants","abstract":"The recent emergence of the SARS-CoV-2 BA.4/5 and BA.2.12.1 variants has led to rising COVID-19 case numbers and concerns over the continued efficacy of mRNA booster vaccination. Here we examine the durability of neutralizing antibody (nAb) responses against these SARS-CoV-2 Omicron subvariants in a cohort of health care workers 1-40 weeks after mRNA booster dose administration. Neutralizing antibody titers fell by ~1.5-fold 4-6 months and by ~2.5-fold 7-9 months after booster dose, with average nAb titers falling by 11-15% every 30 days, far more stable than two dose induced immunity. Notably, nAb titers from booster recipients against SARS-CoV-2 BA.1, BA.2.12.1, and BA.4/5 variants were ~4.7-, 7.6-, and 13.4-fold lower than against the ancestral D614G spike. However, the rate of waning of booster dose immunity was comparable across variants. Importantly, individuals reporting prior infection with SARS-CoV-2 exhibited significantly higher nAb titers compared to those without breakthrough infection. Collectively, these results highlight the broad and stable neutralizing antibody response induced by mRNA booster dose administration, implicating a significant role of virus evolution to evade nAb specificity, versus waning humoral immunity, in increasing rates of breakthrough infection.","journal":"bioRxiv (Cold Spring Harbor Laboratory)","year":2022,"id":298002,"datarank":0.31191623125197543,"base_score":2.0794415416798357,"endowment":2.0794415416798357,"self_citation_contribution":0.31191623125197543,"citation_network_contribution":0.0,"self_endowment_contribution":0.31191623125197543,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":7,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9544,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2022-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":666619,"name":"Julia N. Faraone","orcid":"0000-0002-3421-4707","position":1,"is_corresponding":false},{"id":278003,"name":"John P. Evans","orcid":"0000-0001-8644-5825","position":2,"is_corresponding":false},{"id":278006,"name":"Yi-Min Zheng","orcid":"0000-0002-0394-9735","position":3,"is_corresponding":false},{"id":243261,"name":"Claire Carlin","orcid":"0000-0002-8344-0575","position":4,"is_corresponding":false},{"id":278008,"name":"Gerard Lozanski","orcid":"0000-0002-5095-0456","position":5,"is_corresponding":false},{"id":227281,"name":"Linda J. Saif","orcid":"0000-0002-3224-9009","position":6,"is_corresponding":false},{"id":244459,"name":"Eugene M. Oltz","orcid":"0000-0002-2513-7156","position":7,"is_corresponding":false},{"id":629721,"name":"Richard J. Gumina","orcid":"0000-0001-8298-1129","position":8,"is_corresponding":false},{"id":278009,"name":"Shan‐Lu Liu","orcid":"0000-0003-1620-3817","position":9,"is_corresponding":false},{"id":278005,"name":"Panke Qu","orcid":"0000-0002-0222-365X","position":0,"is_corresponding":true}],"reference_count":17,"raw_metadata":{"citation_network_status":"fetched"},"created_at":"2026-07-19T00:31:31.270564Z","pmid":"35898337","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}